Cargando…

Heated lidocaine/tetracaine patch for treatment of patellar tendinopathy pain

INTRODUCTION: The pain of patellar tendinopathy (PT) may be mediated by neuronal glutamate and sodium channels. Lidocaine and tetracaine block both of these channels. This study tested the self-heated lidocaine-tetracaine patch (HLT patch) in patients with PT confirmed by physical examination to det...

Descripción completa

Detalles Bibliográficos
Autores principales: Gammaitoni, Arnold R, Goitz, Henry T, Marsh, Stephanie, Marriott, Thomas B, Galer, Bradley S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722138/
https://www.ncbi.nlm.nih.gov/pubmed/23888118
http://dx.doi.org/10.2147/JPR.S46239
_version_ 1782278148736417792
author Gammaitoni, Arnold R
Goitz, Henry T
Marsh, Stephanie
Marriott, Thomas B
Galer, Bradley S
author_facet Gammaitoni, Arnold R
Goitz, Henry T
Marsh, Stephanie
Marriott, Thomas B
Galer, Bradley S
author_sort Gammaitoni, Arnold R
collection PubMed
description INTRODUCTION: The pain of patellar tendinopathy (PT) may be mediated by neuronal glutamate and sodium channels. Lidocaine and tetracaine block both of these channels. This study tested the self-heated lidocaine-tetracaine patch (HLT patch) in patients with PT confirmed by physical examination to determine if the HLT patch might relieve pain and improve function. METHODS: Thirteen patients with PT pain of ≥14 days’ duration and baseline average pain scores ≥4 (on a 0–10 scale) enrolled in and completed this prospective, single-center pilot study. Patients applied one HLT patch to the affected knee twice daily for 2–4 hours for a total of 14 days. Change in average pain intensity and interference (Victorian Institute of Sport Assessment [VISA]) scores from baseline to day 14 were assessed. No statistical inference testing was performed. RESULTS: Average pain scores declined from 5.5 ± 1.3 (mean ± standard deviation) at baseline to 3.8 ± 2.5 on day 14. Similarly, VISA scores improved from 45.2 ± 14.4 at baseline to 54.3 ± 24.5 on day 14. A clinically important reduction in pain score (≥30%) was demonstrated by 54% of patients. CONCLUSION: The results of this pilot study suggest that topical treatment that targets neuronal sodium and glutamate channels may be useful in the treatment of PT.
format Online
Article
Text
id pubmed-3722138
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-37221382013-07-25 Heated lidocaine/tetracaine patch for treatment of patellar tendinopathy pain Gammaitoni, Arnold R Goitz, Henry T Marsh, Stephanie Marriott, Thomas B Galer, Bradley S J Pain Res Original Research INTRODUCTION: The pain of patellar tendinopathy (PT) may be mediated by neuronal glutamate and sodium channels. Lidocaine and tetracaine block both of these channels. This study tested the self-heated lidocaine-tetracaine patch (HLT patch) in patients with PT confirmed by physical examination to determine if the HLT patch might relieve pain and improve function. METHODS: Thirteen patients with PT pain of ≥14 days’ duration and baseline average pain scores ≥4 (on a 0–10 scale) enrolled in and completed this prospective, single-center pilot study. Patients applied one HLT patch to the affected knee twice daily for 2–4 hours for a total of 14 days. Change in average pain intensity and interference (Victorian Institute of Sport Assessment [VISA]) scores from baseline to day 14 were assessed. No statistical inference testing was performed. RESULTS: Average pain scores declined from 5.5 ± 1.3 (mean ± standard deviation) at baseline to 3.8 ± 2.5 on day 14. Similarly, VISA scores improved from 45.2 ± 14.4 at baseline to 54.3 ± 24.5 on day 14. A clinically important reduction in pain score (≥30%) was demonstrated by 54% of patients. CONCLUSION: The results of this pilot study suggest that topical treatment that targets neuronal sodium and glutamate channels may be useful in the treatment of PT. Dove Medical Press 2013-07-19 /pmc/articles/PMC3722138/ /pubmed/23888118 http://dx.doi.org/10.2147/JPR.S46239 Text en © 2013 Gammaitoni et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Gammaitoni, Arnold R
Goitz, Henry T
Marsh, Stephanie
Marriott, Thomas B
Galer, Bradley S
Heated lidocaine/tetracaine patch for treatment of patellar tendinopathy pain
title Heated lidocaine/tetracaine patch for treatment of patellar tendinopathy pain
title_full Heated lidocaine/tetracaine patch for treatment of patellar tendinopathy pain
title_fullStr Heated lidocaine/tetracaine patch for treatment of patellar tendinopathy pain
title_full_unstemmed Heated lidocaine/tetracaine patch for treatment of patellar tendinopathy pain
title_short Heated lidocaine/tetracaine patch for treatment of patellar tendinopathy pain
title_sort heated lidocaine/tetracaine patch for treatment of patellar tendinopathy pain
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722138/
https://www.ncbi.nlm.nih.gov/pubmed/23888118
http://dx.doi.org/10.2147/JPR.S46239
work_keys_str_mv AT gammaitoniarnoldr heatedlidocainetetracainepatchfortreatmentofpatellartendinopathypain
AT goitzhenryt heatedlidocainetetracainepatchfortreatmentofpatellartendinopathypain
AT marshstephanie heatedlidocainetetracainepatchfortreatmentofpatellartendinopathypain
AT marriottthomasb heatedlidocainetetracainepatchfortreatmentofpatellartendinopathypain
AT galerbradleys heatedlidocainetetracainepatchfortreatmentofpatellartendinopathypain